Market News & Trends
Sitryx Launches With $30 Million to Develop Disease-Modifying Therapeutics
Sitryx recently announced it has closed its Series A financing round. The company, founded with seed funding from SV Health investors, raised a total of…
BioCorRx Announces Preliminary Agreement With VDM Biochemicals
BioCorRx Inc. recently announced the execution of a letter of intent (LOI) with VDM Biochemicals, Inc. (VDM), subject to execution of a definitive agreement, whereby…
Acquisitions Bolster PCI’s Global Position for Speed-to-Market
PCI Pharma Services’ presence at CPhI Worldwide 2018 (October 9-11, Madrid, Spain – Stand 3F10) highlighted considerable growth and expansion, including acquisition and integration of…
Amicus Therapeutics Enters Research & Development Collaboration
Amicus Therapeutics recently announced a major collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania (Penn) to…
Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases
Wave Life Sciences Ltd. recently announced plans to design and advance stereopure oligonucleotide therapeutics for the potential treatment of rare, inherited eye diseases. Wave’s research…
Ziopharm & Precigen Redefine Relationships, Announce New License Agreement
Ziopharm Oncology, Inc. and Precigen, Inc. recently announced a new definitive license agreement to replace all existing agreements between the companies that will provide Ziopharm with certain exclusive and non-exclusive rights to technology controlled by Precigen, Inc.
Pacific Biosciences Announces a New Paradigm in DNA Sequencing
Pacific Biosciences of California, Inc. recently announced major enhancements to its Sequel System, including a new version (6.0) of its software, new consumable reagents (3.0) and a new SMRT Cell (1M v3).
STRATA Skin Sciences Announces Completion of a Clinical Study
STRATA Skin Sciences recently announced the completion of a multi-center clinical study investigating the efficiency and efficacy of its FDA cleared Multi-Micro Dose (MMD) diagnostic…
Orphazyme Reports Encouraging Arimoclomol Clinical Trial Top-Line Data
Orphazyme A/S recently announced encouraging top-line results for its clinical Phase II/III trial with orally administered arimoclomol for the treatment of patients with Niemann-Pick disease…
Melinta Therapeutics & Menarini Group Enter Commercial Agreement
Melinta Therapeutics, Inc. and Menarini Group recently announced they have entered into an agreement under which Menarini will acquire the exclusive rights to co-develop and…
Dragonfly Therapeutics Announces New Multi-Target Collaboration With Merck
Dragonfly Therapeutics, Inc. recently announced a strategic collaboration with Merck, known as MSD outside the US and Canada, through a subsidiary, to discover, develop, and…
Hitachi Chemical Advanced Therapeutics Solutions Signs 3-Year Agreement With GSK
Hitachi Chemical Advanced Therapeutics Solutions, LLC recently announced it has signed a 3-year clinical manufacturing agreement with GSK. Under the agreement, HCATS will manufacture GSK’s…
Arzeda & BP Sign Collaborative Joint Development Agreement
Arzeda, The Protein Design Company, and BP recently announced a collaboration to develop a process for producing a renewable chemical with broad applications. This collaboration…
A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients
Like all pharmaceuticals, ophthalmic preparations are subject to microbiological contamination. Both ophthalmic solutions used for diagnostic and therapeutic purposes have been found to be contaminated by pathogenic bacteria with reported rates as high as 70%, associated with severe ocular infections such as keratitis and endophthalmitis.
Evonik Launches Advanced Combination Polymer; Sets New Benchmark for Enteric Coatings
Evonik, a global leader for functional excipients used in oral solid dosage forms, recently announced the launch of an advanced combination polymer for enteric coatings.
Aptar Pharma Launches New Portable & Ready-to-Use Upper Respiratory Drug Delivery Solution
Aptar Pharma, a leading drug delivery systems provider, continues its commitment to meeting new market trends with the release of an industry first, PureHale, a new portable and ready-to-use drug delivery solution designed for upper respiratory care.
Ajinomoto Althea & OmniChem Combine to Form Ajinomoto Bio-Pharma Services
Ajinomoto Althea and OmniChem, global leaders in large and small molecule contract manufacturing services, recently announced they are integrating their businesses and operations as a…
Cerecor to Acquire Ichorion Therapeutics; Transaction Worth $26.6 Million
Cerecor Inc. recently announced it has agreed to acquire Ichorion Therapeutics, Inc. Ichorion is a privately-held biopharmaceutical company focused on developing treatments and increasing awareness…
Ovid Therapeutics Announces Initiation of Two Phase 2 Clinical Trials
Ovid Therapeutics Inc. recently announced initiations of the Phase 2 ELEKTRA and ARCADE trials for OV935/TAK-935 in pediatric patients with rare epilepsies. The company reports…
VisionGate Presents Breakthrough Research on Cell-CT Platform
VisionGate recently presented two peer-reviewed poster presentations at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC)…
